Real World Evidence

📊 How is Portugal turning hospital data into powerful population health insights? A new data platform is enabling deeper analysis of health trends, outcomes, and resource use across patient populations. Explore how this approach is advancing data-driven decision-making in healthcare. #SyenzaNews #digitalhealth #HealthTech #DigitalTransformation #datascience

🩺 Could we finally delay the onset of Type 1 diabetes? NICE has recommended teplizumab for people at high risk (stage 2), marking a potential first disease‑modifying option that can postpone progression to clinical disease — a decision driven by trial benefit, patient selection and cost‑effectiveness considerations. Read the full #SyenzaNews analysis to understand what this means for clinicians, payers and patients — and how implementation might unfold. #SyenzaNews #pharmaceuticals #HealthEconomics #healthcarepolicy #costeffectiveness

What does Capvaxive’s pediatric vaccine approval mean for high‑risk youth? 🧒🧪 Regulators have approved Capvaxive for children and adolescents at elevated risk after clinical trials showed strong immune responses and a favorable safety profile. This decision could accelerate targeted rollouts, influence clinical guidance, and shape access strategies for vulnerable populations. Read the full article for trial highlights, rollout timelines, and what clinicians and policymakers need to know. #SyenzaNews #pharmaceuticals #clinicaltrials #MarketAccess #healthcarepolicy

Could Portugal's use of real‑world evidence transform HTA and speed patient access? 🔍🇵🇹 This article explains Portugal’s adaptive HTA pilots — how iterative decision frameworks, real‑world data and stakeholder‑aligned reimbursement models help manage uncertainty while enabling earlier access to innovative therapies. It draws out practical lessons for payers, manufacturers and policymakers aiming to modernize market access. Read the full piece to explore the enablers, pilot insights and implications for future HTA design. #SyenzaNews #HealthEconomics #regulatoryaffairs #MarketAccess #healthcarepolicy

Can AI + real-world evidence transform how medicines are regulated? Regulators are increasingly leveraging RWE and AI to speed approvals, strengthen post‑market surveillance, and enable more patient‑centered decisions — but success depends on data quality, transparent algorithms, and cross‑sector collaboration. This article outlines emerging frameworks, key risks to manage, and practical steps for regulators, industry, and tech partners. Read the full piece to see how stakeholders can responsibly scale RWE and AI in medicines regulation. 🔍 #SyenzaNews #regulatoryaffairs #AIinHealthcare #ai #healthcarepolicy

Can more precise cognitive measurement change how we forecast Parkinson’s progression? The article explores how sensitive cognitive tests, digital assessments and biomarker-informed models — powered by machine learning — can improve accuracy in predicting cognitive decline in Parkinson’s disease, with clear benefits for trial design and personalized care 🧠📈. Read the full piece to see the key methods, validation findings, and practical steps for adopting these tools in research and clinical settings. #SyenzaNews #digitalhealth #AIinHealthcare #ai #datascience

Who’s watching mifepristone’s safety data—and why it matters? 🔬⚖️ A recent safety study reconfirms mifepristone’s established safety profile but highlights gaps in post‑market surveillance and regulatory transparency. These findings could influence oversight practices, prescribing guidance, and access for patients. Read the full article for a clear breakdown of the data, regulatory implications, and what stakeholders should watch next. #SyenzaNews #regulatoryaffairs #pharmaceuticals #healthcarepolicy #governance

Is cancer quietly draining productivity across Asia‑Pacific? 💼📉 This analysis highlights large productivity losses driven by late diagnosis, unequal access to treatment, and weak return‑to‑work support — with sharp disparities between countries and industries. Tackling screening, survivorship care and employer‑led reintegration could recover economic value and improve patient outcomes. Read the full article for country comparisons and practical policy and employer actions. #SyenzaNews #oncology #HealthEconomics #healthcarepolicy #resourceallocation

How do bladder cancer treatments affect patients' quality of life? This article unpacks the real-world consequences of choices from bladder‑sparing therapies to radical cystectomy and urinary diversion—covering impacts on urinary function, sexual health, body image and psychosocial wellbeing. It also highlights the value of patient‑reported outcomes, multidisciplinary care, and emerging approaches that aim to preserve function and dignity. 🔍🩺 Read the full piece to weigh trade‑offs and discover patient‑centered strategies that improve everyday life for people with bladder cancer. #SyenzaNews #oncology #HealthcareInnovation #innovation #healthcarepolicy

Could a mobile app be the difference between a missed dose and better health outcomes? 📱🌍 Sandoz’s mobile-health initiative is using digital tools and community partnerships to expand access to care, support frontline workers, and improve medication adherence in underserved areas. This piece breaks down the program’s approach, early impact, and lessons for scaling mHealth solutions. Read the full article to see how this model could reshape community health delivery. #SyenzaNews #digitalhealth #HealthTech #DigitalTransformation #innovation

New Danish study: no link between prenatal acetaminophen and autism — what does this mean? 💊🔎 A large nationwide cohort analysis in Denmark found no statistically significant association between maternal acetaminophen use during pregnancy and autism after adjusting for confounders, offering reassuring evidence about its safety while noting study limitations. Clinicians and expectant parents should weigh this data alongside other research and clinical guidance. Read the full article for study details, methodology, and practical implications. #SyenzaNews #pharmaceuticals #clinicaltrials #healthcarepolicy #innovation

€250M lost to semaglutide off‑label schemes in Portugal — how did this happen? 🔍 An investigation reveals alleged manipulation of prescriptions and procurement that enabled a €250 million fraud, highlighting serious gaps in regulatory oversight, procurement controls and patient-safety safeguards. Read the full analysis for the timeline, regulatory implications and the governance fixes policymakers and industry must consider. #SyenzaNews #pharmaceuticals #regulatoryaffairs #governance #healthcarepolicy